Android app on Google Play

Myriad Genetics (MYGN) Prolaris Test Shows Recurrence Prostate Cancer Risk

March 5, 2013 7:04 AM EST Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical prostatectomy. The study entitled "Validation of a panel of cell cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," concluded that the Prolaris test effectively stratified men by risk of biochemical recurrence.




You May Also Be Interested In


Related Categories

FDA

Add Your Comment